Next Generation Sequencing in Multiple Myeloma

Munshi, Nikhil C.; Bolli, Niccolò; Minvielle, Stéphane; Anderson, Kenneth C.; Parmigiani, Giovanni; Campbell, Petreena; Avet-Loiseau, H.

doi:10.1016/j.clml.2015.08.004

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, GEP was not uniformly available during the time period of this study, as is available now. The heterogeneity in clinical outcome of multiple myeloma, even in patients with similar risk disease, warrants better tools for risk stratification, possibly by incorporating GEP or next‐generation sequencing (NGS) with revised ISS . Furthermore, refining response criteria with inclusion of minimal residual disease assessment in the existing response criteria will help to better assess the disease status and durability of responses for planning further treatment strategies.…”

Section: Discussionmentioning

confidence: 99%

Predictors of inferior clinical outcome in patients with standard‐risk multiple myeloma

Badar

Srour

Bashir

et al. 2016

European J of Haematology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Predictors of inferior clinical outcome in patients with standard‐risk multiple myeloma

Badar

Srour

Bashir

et al. 2016

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…The study by Walker, Samur, et al and that performed by Munshi et al joins the set of previous studies in identifying TP53, KRAS and NRAS as genes frequently mutated in affected patients and which are associated with a poor prognosis and higher-risk molecular subtypes. The DIS3, FAM46C and CYLD genes also recurrently mutated and which are involved in the pathogenesis of MM [51], [59].…”

Section: Type Of Samplesmentioning

confidence: 99%

Next Generation Sequencing in Diagnosis of Multiple Myeloma

El Fazazi,

Ihlal,

Abbassi

et al. 2023

Preprint

View full text Add to dashboard Cite

Multiple myeloma (MM) is an incurable, diverse cancer in which abnormal plasma cells produce and release monoclonal immunoglobulin (Ig), also known as monoclonal protein or M protein. MM is always preceded by monoclonal gammaglobulinemia of unknown significance (MGUS) and smoldering multiple myeloma (SMM). Diagnosis of MM is made from a bone marrow sample, which involves analysis of the appearance of plasma cells. Quantification of CD138+ plasma cells in core biopsies is performed using techniques such as immunohistochemistry, flow cytometry, fluorescence in situ hybridization (FISH) and conventional cytogenetics. Urinalysis includes total protein by immunofixation and 24-hour urine by serum protein electrophoresis. FISH probes should detect the presence of at least del 13, del 17p, t(4;14), t(11;14), t(14;16), and 1q21 amplifications. Indeed, next-generation sequencing (NGS) has become an increasingly important tool in the diagnosis and treatment of MM. It can be used to identify genetic mutations, copy number changes, and clonal structures to help determine disease prognosis and treatment strategies. NGS can identify subclonal populations of cancer cells that are resistant to therapy and may lead to disease relapse, and can be used to identify potential targets for personalized therapy. For example, NGS can identify mutations in genes involved in drug resistance, enabling the selection of drugs that may be more effective in treating a patient's cancer. This systematic review analyzes 182 papers to determine the position and role of NGS in the diagnosis of MM. We first analyze the platforms and sample types used in the selected studies, and then start discussing the results.

show abstract

Next Generation Sequencing in Multiple Myeloma

Cited by 2 publications

References 0 publications

Predictors of inferior clinical outcome in patients with standard‐risk multiple myeloma

Predictors of inferior clinical outcome in patients with standard‐risk multiple myeloma

Next Generation Sequencing in Diagnosis of Multiple Myeloma

Contact Info

Product

Resources

About